<DOC>
	<DOC>NCT01341912</DOC>
	<brief_summary>The purpose of the study is to study the long-term efficacy, safety and tolerability of Human-cl rhFVIII in previously treated patients with severe hemophilia A.</brief_summary>
	<brief_title>Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Completion of GENA01 study with at least 50 Exposure Days (EDs) and at least 6 months study participation and immediate enrollment into GENA11 Development of FVIII inhibitors (&lt;=0.6 BU), during the course of the GENA01 study Development of any severe liver or kidney disease (ALT and AST level &gt; 5 times of upper limit of normal, creatine &gt;120 micro mol/L) during the course of the GENA01 study</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>